Risk of Leakage of Drug Discovery and Business Development Information
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2020: 1 of 10 companies on the "Worse" side.
15 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「We limit the employees who can access information that must be kept confidential. We also periodically provide information-security training to all officers and employees, raise awareness of the risk of information leakage, use software to prevent leakage caused by negligence, and implement various information-security measures to prevent external intrusion, thereby seeking to reduce this risk.」
The company continues to recognize the risk of leakage of research and customer information and implements access restrictions, training for all personnel, software controls and measures against external intrusion. - FY2023First statedAnnual report
「We possess confidential information concerning technologies and business development both inside and outside the company, including information on drug-discovery targets of pharmaceutical companies. To prevent this information from leaking externally, we are continuously improving our security systems, providing employee training on information handling, managing access privileges and strengthening our internal management structure.」
The company identifies leakage of confidential information as a risk and responds through security improvements, employee training, access-privilege management and strengthened internal controls.